GlassScriptPhysician profile
David F Dieteman
NPI 1427056886
$2,193.82
in general payments reported to CMS, 2019-2025
19 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $302 · 2021: $51.97 · 2022: $389 · 2023: $340 · 2024: $384 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.74 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $544.91 | 2019-2024 | |
| Amgen INC. | $505.94 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $388.92 | 2019-2025 | |
| Dermavant Sciences, INC. | $128.28 | 2022-2024 | Vtama |
| Pfizer INC. | $93.50 | 2019-2024 | |
| Leo Pharma INC. | $92.86 | 2019-2023 | Adbry |
| Abbvie INC. | $85.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $75.34 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $49.61 | 2019 | |
| Galderma Laboratories, L.P. | $41.80 | 2019-2025 | Nemluvio |
| Incyte Corporation | $32.42 | 2023-2024 | Opzelura |
| Prugen, INC. Pharmaceuticals | $31.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.07 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $19.02 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $14.54 | 2020 | |
| Merck Sharp & Dohme LLC | $14.05 | 2019 | |
| Aclaris Therapeutics, INC. | $11.16 | 2019 | |
| Mayne Pharma Commercial LLC | $7.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dieteman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.